Suplatast Tosylate is an inhibitor of Th2 cytokine synthesis which can attenuate IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.
Type 2 helper T cells (Th2) are essential for allergen-induced bronchial hyperresponsiveness and eosinophilic inflammation. Suplatast tosilate is an anti-allergic drug that suppresses IgE synthesis in both mice and humans without affecting total IgG and IgM production[3]. Suplatast tosilate at 1–10µg/mL suppresses human IgE synthesis in a concentration-dependent manner. Suplatast tosilate at 10µg/mL reduced the mRNA level of IL-4 in phytohemagglutinin-stimulated human peripheral blood mononuclear cells[4]. In ovalbumin (OVA)-challenged mice, treatment with 100mg/kg suplatast tosilate significantly decreases the number of total cells and eosinophils in bronchoalveolar lavage fluid compared with OVA control mice. Mice treated with suplatast tosilate also show significantly lower levels of IL-4, IL-5, and IL-13 in mice in comparison with the controls[3].
Suplatast (Tosilate)/甲磺司特 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
DNP-KLH sensitized mice
Oral
10, 30 or 100 mg/kg
Once daily for 5 or 14 days
To evaluate the inhibitory effect of IPD–1151T on bronchoconstriction and IgE production in DNP-KLH sensitized mice. Results showed that IPD–1151T inhibited both antigen- and MCh-mediated bronchoconstriction in a dose-dependent manner and significantly reduced total and specific IgE concentrations in serum.
Mediators Inflamm. 2000;9(2):77-84
BALB/c and C57BL/6 mice
EO771, 4T1 and EMT6 breast cancer models
Intragastrical administration
100 mg/kg
Starting at day four post tumor induction
To evaluate the effect of IPD on breast cancer growth and immune microenvironment. Results showed IPD significantly inhibited tumor growth, promoted Th2 to Th1 switching, and remodeled the immune landscape.
J Transl Med. 2022 Dec 23;20(1):615
Wistar rats
Non-sensitized and sensitized rat model
Oral
100 mg/kg
Once daily for 6 days
To investigate the effect of Suplatast on the half-life of IgE in the circulating blood, results showed that Suplatast facilitated the excretion of IgE from the circulation.
Mediators Inflamm. 2002 Feb;11(1):61-4
BALB/c mice
Allergic disorder model
Intraperitoneal injection
100 mg/kg
Once daily for 14 days
To investigate the effects of IPD-1151T on the expression of co-stimulatory molecules CD40, CD80, and CD86. IPD-1151T significantly suppressed serum IgE levels and decreased IL-4 and IL-5 levels in splenic lymphocytes. Additionally, IPD-1151T suppressed CD40 and CD86 expression but did not affect CD80 expression.
Mediators Inflamm. 2001 Dec;10(6):333-7
BALB/c mice
Tuberculosis model
Subcutaneous injection
16 nmol/g
Once daily for 10 days
Enhance the protective efficacy of BCG vaccine against tuberculosis
搜索
